Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460375 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
A Phase 1 study, sponsored by LigaChem Biosciences.
- Not yet
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
NCT07460375 is a Phase 1 study that has not yet begun recruiting, run by LigaChem Biosciences. The registered enrollment target is 191 participants.
The verdict
NCT07460375, a Phase 1 study, has not yet begun recruiting, sponsored by LigaChem Biosciences.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
Study Summary
This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.
Interventions
- DRUG LCB02A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07460375
The ClinicalTrials.gov registry entry for NCT07460375 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LigaChem Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LCB02A is the first listed.
NCT07460375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07460375 about?
NCT07460375 is a clinical study titled "A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors". This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options ar...
What is the current status of trial NCT07460375?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07460375?
The interventions under investigation include: LCB02A (DRUG).
Who is sponsoring clinical trial NCT07460375?
This trial is sponsored by LigaChem Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.